Medicare Benefits Schedule - Note PN.7.21

Search Results for Note PN.7.21

View Related Items

Category 6 - PATHOLOGY SERVICES

PN.7.21

Note for RhD testing of alloimmunised patients

An alternative test methodology to that used for Item 73420 is recommended to minimise the risk of false negative results in alloimmunised patients, such as using a more sensitive method, confirming the presence of cell-free fetal DNA, or repeat testing of negative results on a second sample. When repeat testing is used to reduce the risk of false negative results, item 73421 should only be billed once.

Related Items: 73421


Related Items

Category 6 - PATHOLOGY SERVICES

73421

73421 - Additional Information

Item Start Date:
01-Jul-2022
Description Updated:
01-Nov-2024
Schedule Fee Updated:
01-Jul-2022

Non-invasive prenatal testing of blood from an RhD negative pregnant patient for the detection of the RHD gene from fetal DNA circulating in maternal blood, if the patient has been previously alloimmunised against RhD

Fee: $550.00 Benefit: 75% = $412.50 85% = $467.50

(See para PN.1.1, PN.7.21 of explanatory notes to this Category)


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change